Literature DB >> 27911121

Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome.

Merve Bicer1, Aslı Guler2, Gokcen Unal Kocabas3, Cetin Imamoglu4, Ali Baloglu5, Oktay Bilgir6, Arif Yuksel6, Giray Bozkaya7, Mehmet Calan3.   

Abstract

PURPOSE: Endocan is a proteoglycan secreted mainly from endothelial cells. It has been implicated that there is a link between endocan and endothelial dysfunction. Polycystic ovary syndrome (PCOS) is a reproductive and metabolic disease associated with increased risk of cardiovascular events. The aims of this study were to ascertain whether circulating endocan levels are altered in women with PCOS, and whether there is an association between endocan and carotid intima media thickness (cIMT).
MATERIALS AND METHODS: This cross-sectional study included 80 women with PCOS and 80 age- and BMI-matched controls without PCOS. Circulating endocan levels were measured using ELISA. Metabolic, hormonal parameters and cIMT were determined. 2-h oral glucose tolerance test (2-h OGTT) was performed on all women.
RESULTS: Circulating endocan levels were significantly elevated in women with PCOS compared with controls (5.99 ± 2.37 vs. 3.66 ± 1.79 ng/ml, P < 0.001). Endocan levels positively correlated with BMI, homeostasis model assessment of insulin resistance (HOMA-IR), free androgen index (FAI), high-sensitivity C-reactive protein (hs-CRP), and cIMT in both PCOS and control groups. Endocan levels did not correlate with fasting blood glucose, 2-h OGTT, A1C and lipid parameters. Multiple linear regression analysis revealed that endocan is an independent predictor for cIMT (β = 0.128, 95% CI = 0.118-0.138, P = 0.011).
CONCLUSIONS: Circulating endocan levels are significantly higher in women with PCOS and endocan is independently associated with cIMT. Elevated endocan levels can be a predictor of increased cardiovascular risk in PCOS subjects.

Entities:  

Keywords:  Carotid intima media thickness; endocan; insulin resistance; polycystic ovary syndrome

Mesh:

Substances:

Year:  2016        PMID: 27911121     DOI: 10.1080/07435800.2016.1255896

Source DB:  PubMed          Journal:  Endocr Res        ISSN: 0743-5800            Impact factor:   1.720


  7 in total

1.  The relationship between serum endocan levels and the presence/severity of isolated coronary artery ectasia.

Authors:  Murat Gök; Harun Kundi; Emrullah Kiziltunç; Canan Topçuoğlu; Ender Örnek
Journal:  Cardiovasc Endocrinol Metab       Date:  2018-05-16

2.  The Effects of Omega-3 and Vitamin E Co-supplementation on Carotid Intima-media Thickness and Inflammatory Factors in Patients with Polycystic Ovary Syndrome.

Authors:  Hamid Reza Talari; Somayyeh Poladchang; Yaser Hamidian; Mansooreh Samimi; Hamid Reza Gilasi; Faraneh Afshar Ebrahimi; Zatollah Asemi
Journal:  Oman Med J       Date:  2018-11

3.  Endocan as a predictor of increased cardiovascular risk during the menopausal transition period.

Authors:  Şükrü Yıldız; Cihan Kaya; Asuman Gedikbaşı; Hüseyin Cengiz; İsmail Alay; Emine Öztürk; Aysun Fendal Tunca; Levent Yaşar
Journal:  Arch Gynecol Obstet       Date:  2020-04-08       Impact factor: 2.344

4.  Is endocan a novel potential biomarker of liver steatosis and fibrosis?

Authors:  Aleksandra Klisić; Nebojša Kavarić; Ludovico Abenavoli; Verica Stanišić; Vesna Spasojević-Kalimanovska; Jelena Kotur-Stevuljević; Ana Ninić
Journal:  J Med Biochem       Date:  2020-09-02       Impact factor: 3.402

Review 5.  Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome.

Authors:  Krystallenia I Alexandraki; Eleni A Kandaraki; Kalliopi-Anna Poulia; Christina Piperi; Eirini Papadimitriou; Theodoros G Papaioannou
Journal:  touchREV Endocrinol       Date:  2021-04-28

6.  Serum endocan levels in relation to traditional and non-traditional anthropometric indices in adult population.

Authors:  Aleksandra Klisić; Nebojša Kavarić; Vesna Spasojević-Kalimanovska; Jelena Kotur-Stevuljević; Ana Ninić
Journal:  J Med Biochem       Date:  2021-01-26       Impact factor: 3.402

7.  Endocan expression is correlated with poor progression-free survival in patients with pancreatic neuroendocrine tumors.

Authors:  Liang-Yu Lin; Yi-Chen Yeh; Chia-Huei Chu; Justin G S Won; Yi-Ming Shyr; Yee Chao; Chung-Pin Li; Shin-E Wang; Ming-Huang Chen
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.